First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.
暂无分享，去创建一个
L. Antonuzzo | A. Zaniboni | F. Loupakis | R. Murialdo | F. Morano | F. Pietrantonio | F. de Braud | C. Cremolini | C. Antoniotti | S. Cinieri | M. Tampellini | M. Clavarezza | S. Corallo | L. Procaccio | V. Smiroldo | A. Raimondi | R. Berenato | M. Di Bartolomeo | S. Bustreo | G. Tomasello | G. Peverelli | A. Bianchi